Ingrezza Miss Takes Neurocrine Biosciences (NBIX) PT Down To $110 At Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Neurocrine Bio. (NBIX) PT Lowered to $102 at H.C. Wainwright
December 13, 2018 11:09 AM ESTH.C. Wainwright analyst Andrew Fein lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $102.00 (from $162.00) while maintaining a Buy rating.
... MoreNeurocrine Bio. (NBIX) PT Lowered to $105 at Oppenheimer
December 13, 2018 9:30 AM ESTOppenheimer analyst Jay Olson lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $105.00 (from $140.00) while maintaining a Outperform rating.
Olson commented, "T-Force-GOLD missed the primary endpoint, sending NBIX shares down 14% on 12/12 (vs. NBI +1.3% and S&P 500 +0.5%) on the loss of this important... More
